Highest-materiality recent filing
Syra Health posts first profitable quarter in Q1 2026; net income $241K, EPS $0.02, revenue up 22%
Net income of $241,000 vs net loss of $(472,265) in Q1 2025; EPS $0.02 vs ($0.04).
Syra Health FY2025 net loss down 76%; Population Health revenue up 157% to $5.3M
FY2025 revenue $7.2M (-9% YoY); net loss improved 76% to ($896K) from ($3.8M).
Syra Health appoints Gregory R. Alexander as CEO effective Jan 5, 2026
New CEO Gregory R. Alexander receives $251k base salary, 30% target bonus, and 110,537 RSUs.
Syra Health amends charter to modify Class B conversion triggers and transfer rules
Stockholders approved charter amendments on Nov 14, 2025; Certificate of Amendment filed and effective Nov 18, 2025.
Syra Health shareholders approve Class B charter amendments and elect directors
All five director nominees elected; top vote-getter Priya Prasad 9,093,067 for, 4,508,108 against.
Syra Health Q3 revenue falls 26% to $1.7M; population health up 96%, net loss down 46%
Revenue $1.7M, down from $2.3M YoY due to federal spending cuts.
Syra Health appoints Radhika Mereddy to Board of Directors
Radhika Mereddy appointed to Syra Health's Board on August 13, 2025.
Syra Health Q2 net loss narrows 95% to $64K; gross margin surges to 38.7%
Net loss of $64K ($0.01 EPS) vs $1.4M loss ($0.21 EPS) in Q2 2024; adjusted EBITDA improved to ($54K) from ($1.4M).
Director Deepika Vuppalanchi resigns from Syra Health board for personal reasons
Deepika Vuppalanchi resigned from the Board of Directors on July 28, 2025, for personal reasons.
Syra Health terminates CEO Deepika Vuppalanchi for cause; CFO appointed interim CEO
Board terminated CEO Deepika Vuppalanchi for cause on June 13, 2025.
Syra Health board launches national CEO search; Vuppalanchi interim
Board initiates a national search for a new CEO to succeed current CEO Dr. Deepika Vuppalanchi.
Syra Health Q1 revenue $1.9M (+6% YoY); net loss narrows to ($472K); withdraws 2025 guidance
Revenue $1.9M (+6% YoY); Population Health revenue tripled to $1.2M.
Director Andrew Dahlem resigns from Syra Health board for personal reasons
Andrew Dahlem resigned from the Board of Directors on April 25, 2025.
Andrew Dahlem appointed Chairman of the Board at Syra Health
Andrew Dahlem agreed to become Chairman of the Board.
Syra Health FY 2024 revenue $8.0M (+45% YoY); Q4 net loss nearly halved to $504K; PopHealth up 132%
FY 2024 revenue $8.0M (+45% YoY); net loss $3.8M vs $2.9M in 2023.
Syra Health Executive Chairman and President Sandeep Allam passes away
Notified on January 15, 2025 of Sandeep Allam's death.
Syra Health regains Nasdaq compliance on minimum equity requirement
Received Nasdaq deficiency notice Aug 13, 2024 for failing minimum $2.5M stockholders' equity.
Syra Health reports Q3 2024 revenue $2.3M (+42% YoY); net loss narrows 69% sequentially to $417K
Revenue $2.3M, up 42% YoY from $1.6M; Population Health +36%, Healthcare Workforce +54%.
Syra Health receives Nasdaq delisting notice for bid price below $1.00 for 30 consecutive days
Nasdaq notified Syra Health on Oct 18, 2024 that its common stock bid price closed below $1.00 for 30 business days, violating Listing Rule 5550(a)(2).
Nasdaq notified Syra Health of non-compliance with stockholders' equity minimum of $2.5M (Listing Rule 5550(b)(1)).
Syra Health Q2 revenue $2.0M (+101% YoY); net loss widens to $1.4M
Revenue $2.0M vs $1.0M in Q2 2023; Population Health grew 276% YoY, Healthcare Workforce 66%.
Syra Health Corp. 2024 annual meeting: all 8 director nominees elected and auditor ratified
15,222,830 shares represented at the Annual Meeting held June 18, 2024.
Syra Health Q1 revenue up 47% to $1.7M, net loss widens to $1.4M; FY2024 guidance $9-11M
Revenue $1.7M vs $1.2M Q1 2023; Population Health grew 212% YoY; Healthcare Workforce up 28%.
Syra Health appoints COO and CFO Priya Prasad to board of directors
On March 27, 2024, Syra Health Corp. appointed Priya Prasad, its COO and CFO, as a director.
Syra Health 2023 revenue $5.5M, net loss $2.94M; projects 64-100% growth in 2024
FY2023 revenue $5.5M, net loss $(2.94M), vs $5.6M and $(2.12M) in 2022.
Syra Health Q3 revenue up 4% to $1.58M; net loss flat at $354K; Digital Health posts first revenue
Revenue $1.58M (+4% YoY); Digital Health unit generated first revenues of $131,356.
Syra Health prices upsized IPO of 1.615M units at $4.125/unit, raises ~$6.7M gross
IPO units priced at $4.125 each: one share Class A common + one warrant (exercise $6.50, 5-year term).
the Board of Directors of the Company appointed Priya Prasad, the Company’s CFO and COO, as interim CEO.
On April 25, 2025, Andrew Dahlem resigned from the Board of Directors of Syra Health Corp. (the “Company”) for personal reasons.
On March 27, 2024, the Board of Directors of Syra Health Corp. (the “Company”) appointed Priya Prasad, the Company’s COO and CFO as a director of the Company.
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Max materiality 0.80 · Median 0.65 · Most common event earnings